Pioglitazone could induce remission in major depression: a meta-analysis
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Background: Pioglitazone, a selective agonist of the nuclear transcription factor peroxisome proliferator-activated receptor-gamma (PPAR-γ), prescribed for the treatment of type 2 diabetes, could have antidepressant properties. However, its potential to induce remission of major depressive episodes, the optimal clinical target for an antidepressant drug, is a matter of concern. Indeed, only one out of four double-blind randomized controlled trials show higher remission rates with pioglitazone than with control treatments. Hence, the main aim of this study was to perform a meta-analysis of the efficacy of pioglitazone for the treatment of MDE, focusing on remission rates. Methods: Four double-blind randomized controlled trials, comprising 161 patients with an MDE, were included in this meta-analysis. Pioglitazone was studied either alone (one study) or as add-on therapy to conventional treatments (antidepressant drugs or lithium salts). It was compared either to placebo (three studies) or to metformin (one study). Remission was defined by a Hamilton Depression Rating Scale score <8 after treatment. Results: Pioglitazone could induce higher remission rates than control treatments (27% versus 10%, I 2 =17.3%, fixed-effect model: odds ratio [OR] =3.3, 95% confidence interval [95% CI; 1.4; 7.8], P =0.008). The OR was even higher in the subgroup of patients with major depressive disorder (n=80; 23% versus 8%, I 2 =0.0%; fixed-effect model: OR =5.9, 95% CI [1.6; 22.4], P =0.009) and in the subgroup of patients without metabolic comorbidities (n=84; 33% versus 10%, I 2 =0.0%; fixed-effect model: OR =5.1, 95% CI [1.5; 17.9], P =0.01). As compared to control treatments, results suggest six patients would need to be treated with pioglitazone in order to achieve the possibility of one more remission. Conclusion: Pioglitazone, either alone or as add-on therapy to conventional treatments, could induce remission of MDE, suggesting that drugs with PPAR-γ agonist properties may be true and clinically relevant antidepressants, even in patients without metabolic comorbidities. Keywords: pioglitazone, major depressive episode, major depressive disorder, bipolar disorder, remission, meta-analysis
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
Vos, T., Barber, R. M., Bell, B., Bertozzi-Villa, A., Biryukov, S., Bolliger, I., Charlson, F., Davis, A., Degenhardt, L., Dicker, D., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60692-4 · Cited by 6,414
Frank, E. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810330075011 · Cited by 1,959
Depression and Type 2 Diabetes Over the Lifespan
Mezuk, B., Eaton, W. W., Albrecht, S., & Golden, S. H. (2008) · Diabetes Care · doi:10.2337/dc08-0985 · Cited by 1,558
Major depressive disorder: new clinical, neurobiological, and treatment perspectives
Kupfer, D. J., Frank, E., & Phillips, M. L. (2012) · The Lancet · doi:10.1016/s0140-6736(11)60602-8 · Cited by 894 · cited 1×
“Introduction Major depressive episodes are a severe public health problem, with a major impact on morbidity and mortality.(1,2) However, the efficacy of conventional antidepressant drugs in the treatment of MDE is low, both in major depressive disorder (MDD) and in bipolar disorder (BD).”
BackgroundBidirectional Association Between Depression and Metabolic Syndrome
Pan, A., Keum, N., Okereke, O. I., Sun, Q., Kivimaki, M., Rubin, R. R., & Hu, F. B. (2012) · Diabetes Care · doi:10.2337/dc11-2055 · Cited by 772
Report by the ACNP Task Force on Response and Remission in Major Depressive Disorder
Rush, A. J., Kraemer, H. C., Sackeim, H. A., Fava, M., Trivedi, M. H., Frank, E., Ninan, P. T., Thase, M. E., Gelenberg, A. J., Kupfer, D. J., et al. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301131 · Cited by 707
Perlis, R. H., Ostacher, M. J., Patel, J. K., Marangell, L. B., Zhang, H., Wisniewski, S. R., Ketter, T. A., Miklowitz, D. J., Otto, M. W., Gyulai, L., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.2.217 · Cited by 689 · cited 1×
“However, the efficacy of conventional antidepressant drugs in the treatment of MDE is low, both in major depressive disorder (MDD) and in bipolar disorder (BD).(3,4) Approximately half of adults with an MDD do not achieve sustained remission despite successive adequate conventional antidepressant drug trials.”
Neuroimmune mechanisms of depression
Hodes, G. E., Kana, V., Menard, C., Merad, M., & Russo, S. J. (2015) · Nature Neuroscience · doi:10.1038/nn.4113 · Cited by 585
Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists
Kapadia, R. (2008) · Frontiers in Bioscience · doi:10.2741/2802 · Cited by 433
Cited by
The Bidirectional Relationship of Depression and Inflammation: Double Trouble
Beurel, E., Toups, M., & Nemeroff, C. B. (2020) · Neuron · doi:10.1016/j.neuron.2020.06.002 · Cited by 2,136
Social Defeat Modulates T Helper Cell Percentages in Stress Susceptible and Resilient Mice
Ambrée, O., Ruland, C., Zwanzger, P., Klotz, L., Baune, B. T., Arolt, V., Scheu, S., & Alferink, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20143512 · Cited by 54
Gamble, J.-M., Chibrikov, E., Midodzi, W. K., Twells, L. K., & Majumdar, S. R. (2018) · BMJ Open · doi:10.1136/bmjopen-2018-023830 · Cited by 52
Metadata
- Authors
- Colle, R., de Larminat, D., Rotenberg, S., Hozer, F., Hardy, P., Verstuyft, C., Fève, B., & Corruble, E.
- Venue
- Neuropsychiatric Disease and Treatment
- Publisher
- Informa UK Limited
- Published
- 2016-12
- Volume
- Volume 13
- Pages
- 9-16
- ISSN
- 1176-6328 (ISSN-L)
- 1178-2021
- OpenAlex
- W2564398793
- Cited by
- 73
- References
- 15
- FWCI
- 1.93
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pioglitazone could induce remission in major depression: a meta-analysis. https://app.cochat.ai/papers/10.2147/ndt.s121149
- The paper
- Colle, R., de Larminat, D., Rotenberg, S., Hozer, F., Hardy, P., Verstuyft, C., Fève, B., & Corruble, E. (2016). Pioglitazone could induce remission in major depression: a meta-analysis. Neuropsychiatric Disease and Treatment. https://doi.org/10.2147/ndt.s121149
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.